Women’s health experts have issued a warning about the limitations of the first-of-its-kind endometriosis treatment pill, which was approved for NHS use this week.
The combination drug, relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), is the first long-term daily pill licensed to treat endometriosis.